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Bacillus sp. P34, a strain isolated from aquatic environments of Brazilian Amazon basin, produces
a bacteriocin-like substance (BLS) which was encapsulated in nanovesicles prepared from partially
puriﬁed soy lecithin. The efﬁciency of free and encapsulated BLS P34 to control the development of
L. monocytogenes and maintenance of antimicrobial activity was assessed over time in milk. The anti-
microbial activity of free and encapsulated BLS P34 decreased approximately 50% after 4 days of storage
(<4 C) in skim and whole milk. After this period there was not signiﬁcant loss of activity up to 21 days.
The viable counts of Listeria monocytogenes in skim and whole milk containing 3200 AU/ml of free or
encapsulated BLS P34 were always lower than those observed in controls without bacteriocin at both
30 C and 7 C. At 1600 AU/ml concentration, free and encapsulated BLS P34 were inhibitory to
L. monocytogenes in skim milk, when compared with the control at 7 days. Nanovesicle-encapsulated and
free BLS P34 shows potential use as biopreservative for application in milk-derived products.
 2011 Elsevier Ltd.Open access under the Elsevier OA license.1. Introduction
Bacteriocins are antimicrobial peptides widespread produced
among bacteria that may show varied antimicrobial spectra (Cotter,
Hill, & Ross, 2005). Those produced by Gram-positive bacteria,
particularly by lactic acid bacteria, have been largely studied with
the perspective of food protection against pathogenic and spoilage
microorganisms (Arauz, Jozala, Mazzola, & Penna, 2009; Cleveland,
Montville, Nes, & Chikindas, 2001). Their proteinaceous nature
implies a putative degradation in the gastro-intestinal tract of
human and animals, suggesting that some bacteriocin-producing
lactic acid bacteria or puriﬁed bacteriocins could be used as
natural preservatives in foods (Cleveland et al., 2001). Bacteriocins
are also produced by several other classes of bacteria (Riley &
Wertz, 2002).
Bacillus has been reported as a safe and interesting bacterial
genus for utilization in food industry (Pedersen, Bjørnvad,
Rasmussen, & Petersen, 2002). Production of bacteriocins or
bacteriocin-like substances (BLS) has been described for many
species of the genus Bacillus including B. subtilis (Zheng, Yan,
Vederas, & Suber, 1999), B. thuringiensis (Kamoun et al., 2005),
B. amyloliquefaciens (Lisboa, Bonatto, Bizani, Henriques, & Brandelli,x: þ55 51 3308 7048.
sevier OA license.2006), Bacillus licheniformis (Cladera-Olivera, Caron, & Brandelli,
2004) and B. cereus (Bizani & Brandelli, 2002). Bacillus sp. strain
P34 was isolated from aquatic environments of Brazilian Amazon
basin, and its antimicrobial activity was described as a BLS active
against important Gram-positive pathogenic bacteria like Listeria
monocytogenes and Bacillus cereus (Motta, Cladera-Olivera, &
Brandelli, 2004). This antimicrobial substance has amolecular mass
of 1456 Da, was relatively heat stable and sensitive to proteolytic
enzymes (Motta, Cannavan, Tsai, & Brandelli, 2007a). In cytotoxicity
tests, BLS P34 shows similar behavior to nisin, a bacteriocin wide
accepted for utilization in food industry (Vaucher, Motta, &
Brandelli, 2010).According to its properties of size and protein
stability data, BLS P34 could be associated with the group of
Listeria-active class Ib bacteriocins (Motta, Lorenzini, & Brandelli,
2007b). This antimicrobial substance has the cell membrane as
target of action, promoting loss of protoplasmic material and
consequently the death of the cell (Motta, Flores, Souto, & Brandelli,
2008).
Bacteriocins or bacteriocin-like substances can lose their anti-
microbial activity in many food products for a variety of reasons.
Interference and cross-reactions of the antimicrobial with various
food constituents, such as protein and fat, are difﬁcult to overcome
and often require large amounts of antimicrobial in order to gain
signiﬁcant reductions in the pathogen load in a product (Taylor,
Bruce, Weiss, & Davidson, 2008). The efﬁciency of these peptides
in food products may be increased by their incorporation into
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endogenous food proteases or binding to food compounds (Laridi
et al., 2003; Malheiros, Daroit, & Brandelli, 2010; Malheiros,
Daroit, Silveira, & Brandelli, 2010; Teixeira, Santos, Silveira, &
Brandelli, 2008; Were, Bruce, Davidson, & Weiss, 2003). Lipo-
some, a closed phospholipid bilayer membrane, has a nano-order
interface harboring hydration layer and non-polar (hydrophobic)
layer on its surface. Due to the presence of both lipid and aqueous
phases in the structure of lipid vesicles, they can be utilized in the
entrapment, delivery, and release of water-soluble, lipid-soluble,
and amphiphilic materials (Khosravi-Darani, Pardakhty,
Honarpisheh, Rao, & Mozafari, 2007; Mozafari, Johnson,
Hatziantoniou, & Demetzos, 2008).
Nanovesicles to delivery of bioactive components with
substantiated health beneﬁts of the foods will be required to meet
the challenges in developing healthy foods, which are aimed at
reducing the risks of target diseases in a population (Sanguansri &
Augustin, 2006). A microorganism that causes disease is L. mono-
cytogenes, which is capable of surviving environmental conditions
that are normally fatal to many other bacteria, enabling this path-
ogen to remain active in foods and eventually establish infection
after consumption (Cunningham, O’Byrne, & Oliver, 2009). The aim
of the present study was to assess the effect of free and
nanovesicles-encapsulated BLS P34 against L. monocytogenes in
milk. Thereafter, the maintenance of antimicrobial activity was
assessed over time in milk.
2. Materials and methods
2.1. Bacterial strains and media
Bacillus sp. P34, an isolate from intestine of the teleost Piau-
com-pinta (Leporinus sp.) from Amazon basin, was the producer
strain and was previously characterized (Motta et al., 2004). L.
monocytogenes ATCC 7644 was used as the indicator organism for
the bacteriocin activity assay. The strains were maintained on BHI
agar plates at 4 C, and subcultured periodically. Before each
experiment, this strain was grown in BHI medium at 37 C for
18e24 h in a rotary shaker (180 rpm).
2.2. Production of BLS P34
For the production of BLS, the producer strain was aerobically
cultivated in 150 ml BHI medium in orbital shaker at 180 rpm for
24 h. The culture was centrifuged at 10,000 g for 15 min at 4 C, and
the supernatant was sterilized with a 0.22 mm membranes. The
ﬁltrate was precipitated with ammonium sulfate at 20% saturation.
The precipitate was dissolved in 10 mmol/l sodium phosphate
buffer pH 7.0. This solution was further puriﬁed by gel ﬁltration
chromatography on a Sephadex G-100 column, and active fractions
were pooled. The partially puriﬁed BLS P34 was stored in sterile
ﬂasks at 4 C until used (Motta et al., 2007b).
2.3. BLS P34 encapsulation
Encapsulation of BLS P34 in nanovesicles of partially puriﬁed
soybean phosphatidylcholine (PC-1; Mertins, Sebben, Schneider,
Pohlmann, & Silveira, 2008) was carried out by the thin-ﬁlm
hydration method according to Malheiros, Micheletto, Silveira &
Brandelli, 2010. Summarizing, PC-1 was dissolved in chloroform
and the solvent was removed by a rotary evaporator until a thin
ﬁlm was formed on the ﬂask walls. The dried lipid ﬁlm was
dispersed by the addition of sodium phosphate buffer containing
BLS P34. These mixtures were then agitated (60 C) and sonicated
in bath-type ultrasound (40 kHz, Unique USC 700). The size ofnanovesicles was determined by light scattering (Teixeira et al.,
2008). The entrapment efﬁciency (EE) was determined using
antimicrobial activity assay. Discrimination of encapsulated from
non-encapsulated BLS P34 was performed by ultraﬁltration
(Ultracel YM-50 Membrane, Millipore) and the EE was calculated
(Malheiros, Micheletto, Silveira, et al., 2010).2.4. Antimicrobial activity assay
Antimicrobial activity was determined essentially as described
elsewhere (Motta & Brandelli, 2002). BLS P34 was diluted by serial
two-fold dilution method (1, 1/2, 1/4, 1/8, 1/16, 1/32, 1/64, 1/128),
and an aliquot of 10 ml each dilution was applied onto BHI agar
plates inoculated with a swab submerged in L. monocytogenes ATCC
7644 (approximately 7 log CFU/ml). Activity was deﬁned as the
reciprocal of the dilution after the last serial dilution giving a zone
of inhibition and was expressed as activity unit (AU) per milliliter.2.5. Determination of BLS P34 activity in milk
UHT skim milk (0% fat) and UHT whole milk (3.25% fat) were
purchased from a local market. Free and nanovesicles-encapsulated
BLS P34 was independently applied to skim and whole milk to
produce an initial activity of 800 AU/ml. The samples were kept
under refrigeration (4 C) and the antimicrobial activity was eval-
uated by 21 days as described above.2.6. Inhibitory effect of free and encapsulated BLS P34 in milk
L.monocytogenes culture (9 log CFU/ml) was diluted in saline
solution (8.5 g/l NaCl) to count approximately 6 log CFU/ml, and
500 ml of this suspension was added to 10 ml of whole and skim
milk. After, 1 ml of free and nanovesicles-encapsulated BLS P34
(3200 AU/ml) was added to tube. Controls were inoculated with
L. monocytogenes and sodium phosphate buffer (10 mmol/l pH 7.0).
The tubes were incubated for 0, 2, 4, 6 and 24 h at 30 C.
The effect of 1600 AU/ml and 3200 AU/ml of free and encap-
sulated BLS P34 was assessed in whole and skim milk at refriger-
ation temperature (7  1 C). Counts of L. monocytogenes were
estimated at 0, 7 and 14 days for 1600 AU/ml and 0, 2, 5, 8,10 and 14
days for 3200 AU/ml (Malheiros, Daroit, Silveira, et al., 2010). The
quantiﬁcation of L. monocytogenes was performed by the drop
culture method (Malheiros, Brandelli, Noreña, & Tondo, 2009). The
colonies were counted in BHI agar plates after 24 h of incubation at
37 C.2.7. Statistical analysis
All experimental treatments were tested in duplicate, and
averages were calculated for treatments at each time point.
Obtained counts were compared using test t of Tukey. Data analyses
were performed with the software Statistica 7.1, and differences
were considered signiﬁcant at P < 0.05.3. Results
3.1. Encapsulation of BLS P34
BLS P34 was encapsulated into nanovesicles of partially puriﬁed
soybean phosphatidylcholine by hydration ﬁlm method. Nano-
vesicles presented a mean diameter of 160 nm and the entrapment
efﬁciency was 100%.
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The antimicrobial activities of free and encapsulated BLS P34
were evaluated for a period of 21 days in milk (Fig. 1). It was
observed that there was no signiﬁcant difference (P > 0.05) in
antimicrobial activity between skim and whole milk. There was
a loss of approximately 50% of antimicrobial activity after 4 days of
storage at 4 C in both samples containing free or encapsulated BLS
P34. After this period there was no signiﬁcant loss of activity for up
to 21 days for all samples and treatments.
3.3. Inhibitory effect of free and encapsulated BLS P34 in milk
Free BLS P34 (3200 AU/ml) caused a decrease in L. mono-
cytogenes counts below the detection limit of the method on skim
milk at 30 C during 6 h; however, after 24 h of incubation theFig. 1. Residual antimicrobial activity of free and encapsulated BLS P34 in skim milk
(A) and whole milk (B) as a function of storage time at 4 C. (-) Free BLS P34 and (C)
encapsulated BLS P34. Values are means of two independent experiments.microbial counts were of approximately 4 log CFU/ml. When
encapsulated BLS P34was tested, it was observed 2 log reduction in
counts of L. monocytogenes at 6 h without signiﬁcant increase until
24 h (Fig. 2A). A decrease of 4 log cycles in L. monocytogenes counts
was observed for free and encapsulated BLS P34 versus control at
24 h in skim milk at 30 C. In the case of whole milk at 30 C, it was
not observed signiﬁcant growth of L. monocytogenes for free and
encapsulated BLS P34 until 6 h (Fig. 2B). Only after 24 h there was
signiﬁcant (P < 0.05) growth of L. monocytogenes (for both treat-
ments), but 1-2 log cycles lower than the control.
Two concentrations of BLS P34 were tested for refrigeration
temperature (7  1 C). At lower concentration (1600 AU/ml) in
skim milk, free and encapsulated BLS P34 were inhibitory to
L. monocytogenes cells compared to the control (w2.5 log CFU/ml
reduction) at 7 days (Fig. 3A). In whole milk both treatments tested
showed no inhibitory effect on the pathogen for up to 14 days
(Fig. 3B).
A concentration of 3200 AU/ml of free or encapsulated BLS P34
was very effective in reducing viable counts in skim milk (Fig. 4A).
In the second day of incubation encapsulated BLS P34 showed
a decrease of 2.5 log CFU/ml compared to the control, whereas free
BLS P34 caused a decrease in L. monocytogenes counts below theFig. 2. Viable cell counts of Listeria monocytogenes, confronted to 3200 AU/ml of free
BLS P34 (C), encapsulated BLS P34 (:) and control (-) in skim milk (A) and whole
milk (B) at 30 C.
Fig. 3. Viable cell counts of Listeria monocytogenes in skim milk (A) and whole milk (B)
at 7  1 C, confronted to 1600 AU/ml of free BLS P34 (C), encapsulated BLS P34 (:)
and control (-).
Fig. 4. Viable cell counts of Listeria monocytogenes in skim milk (A) and whole milk (B)
at 7  1 C, confronted to 3200 AU/ml of free BLS P34 (C), encapsulated BLS P34 (:)
and control (-).
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differences (P > 0.05) between treatments. Free and encapsulated
BLS P34 treatments consistently lowered L. monocytogenes counts
below the detection limit of the method at days 5 and 8, increasing
thereafter. In whole milk, free and encapsulated BLS P34 presented
no signiﬁcant reduction (P < 0.05) in bacterial population during
the ﬁrst 2 days. However, after 5 days both treatments decreased
the population of L. monocytogenes by 1e2 log cycles compared to
the control (Fig. 4B).4. Discussion
We have earlier reported that BLS P34 was inhibitory to a broad
spectrum of indicator strains, including several spoilage and
pathogenic microorganisms (Motta, Cannavan, Tsai, & Brandelli,
2007a). Moreover, this antimicrobial substance presented low
in vitro toxicity to eukaryotic cells with similar effect to that
observed for nisin, suggesting to be safe for food use (Vaucher et al.,
2010).
In this study, the antimicrobial activity of free and nanovesicles-
encapsulated BLS P34 was assessed in skim and whole milk asa function of storage time at 4 C. The initial decrease (after 4 days)
of antimicrobial activity of BLS P34 in skim and whole milk may be
associated to interaction with the milk proteins, which can bind
somehow with BLS P34 as suggested for nisin (Jung, Bodyfelt, &
Daeschel, 1992). It was observed that the milk fat content and the
encapsulation in nanovesicles did not inﬂuence the antimicrobial
activity of BLS P34. In contrast, the negative effect of fat on anti-
microbial activity of nisin is extensively reported, caused by the
peptide adsorption onto fat globules (Bhatti, Veeramachaneni, &
Shelef, 2004; Chollet, Sebti, Martial-Gros, & Degraeve, 2008; Jung
et al., 1992). Jung et al. (1992) reported that nisin activity against
L. monocytogenes dropped by 33% in skim milk, by 50% in milk with
1.2% fat, and by 88% in milk with 12.9% fat. More recently, Chollet
et al. (2008) observed that a 30% fat (w/w) level in gel gave rise
to a signiﬁcant decrease (P < 0.01) in nisin antimicrobial activity
against K. rhizophila. Encapsulation of BLS P34 in liposomes main-
tains the same inhibitory effect against L. monocytogenes than free
BLS P34. Teixeira et al. (2008) suggest controlled release of the
antimicrobial peptide from the vesicle and/or slower diffusion on
semisolid agar medium, since to these authors a higher dosage of
liposome-encapsulated bacteriocin was necessary to obtain the
same inhibitory effect observed for the free bacteriocin.
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sulated BLS P34 was similar in skim and whole milk, the inhibition
of L. monocytogenes by free and encapsulated BLS P34 was espe-
cially observed in skim milk. In accordance, the antimicrobial
peptide nisin was more effective in reducing the initial population
of L. monocytogenes in brain-heart infusion broth and in skim milk
than fat milk (Jung et al., 1992). Therefore, higher concentration of
nisin it is necessary to control the growth this bacteria in whole
milk (Malheiros, Daroit, Silveira, et al., 2010).
Bacteriostatic effect was observed in skim milk at 30 C using
encapsulated BLS P34 (3200 AU/ml) treatment. However, when free
BLS P34was tested, L. monocytogeneswere reduced to counts below
the detection limit during the ﬁrst 6 h. Therefore, the free BLS P34
inhibited the target pathogen in the ﬁrst moment possibly to injure
the bacteria, while encapsulated BLS P34 was possibly being
released over time maintaining the same initial count by 24 h.
Nisin, an antimicrobial peptide recognized as safe for food appli-
cations by the Joint Food and Agriculture Organization/World
Health Organization (FAO/WHO) Expert Committee on Food
Additivies, was encapsulated in liposomes and tested against
L. monocytogenes in BHI medium and skimmilk at 30 C (Malheiros,
Daroit, Silveira, et al., 2010). At such abuse temperature conditions,
these authors found that free nisin showed better inhibitory than
the liposomal counterparts. Taylor et al. (2008) evaluated the effect
of nisin encapsulated in puriﬁed phosphatidylcholine liposomes to
inhibition of L. monocytogenes growth. Those authors observed
inhibition of about 60% of pathogens by free and encapsulated nisin
after 48 h of incubation at 32 C on double-strength BHI medium.
Antimicrobial activity of bacteriocins in food matrix is affected by
several factors, such as temperature to storage, fat and protein
content and cation concentrations. This was demonstrated in the
work from Branen and Davidson (2004), when nisin did not
inhibited L. monocytogenes in 2% fat milk stored at 25 C for 24.
Bacteriocins have been used to inhibit L. monocytogenes in ﬂuid
systems. The addition of the antimicrobial peptide cerein 8A (ﬁnal
concentration of 160 AU/ml) to UHTmilk resulted in a decrease of 3
log cycles in viable cells of L. monocytogenes within the 14-day
period at 4 C (Bizani, Morrissy, Dominguez, & Brandelli, 2008). In
this study free and encapsulated BLS P34 at ﬁnal concentration of
160 AU/ml was bacteriostatic by 7 days to 7 C in skim milk.
However, according to Motta et al. (2007a) this same antibacterial
substance was bactericidal and bacteriolytic (ﬁnal concentration of
160 AU/ml) to L. monocytogenes after 6 h of growth in TSB medium
at 37 C. In whole milk the treatment tested was not effective to
decrease of growth of L. monocytogenes to 7 C.
Free and encapsulated BLS P34 at 3200 AU/ml consistently
lowered L. monocytogenes counts below the detection limit of the
method at days 5 and 8 in skim milk. In whole milk, after 5 days
both treatments decreased the population of L. monocytogenes 1-2
log cycles compared to the control. Malheiros, Daroit, Silveira, et al.,
2010a observed that in skim milk, encapsulated and free nisin (0.5
and 0.1 mg/ml) treatments consistently lowered L. monocytogenes
counts below the detection limit (<1.69 log CFU/ml) during
a period of 14 days, however, in whole milk, only the highest
concentration (0.5 mg/ml) of nisin reduced bacterial counts. It is
important to note that antilisterial activities of nisin are well
documented; however chemical composition and treatment of
a food may play an important role in its antilisterial effects (Bhatti
et al., 2004).
Antimicrobials peptides could be present both in the aqueous
and lipids phases of liposomes. Then, might be able to effectively
provide both short-term (by release of encapsulated bacteriocin)
and long-term (desorption of membrane-immobilized bacteriocin)
antibacterial actions (Benech, Kheadr, Lacroix, & Fliss, 2002; Taylor
et al., 2008).5. Conclusions
The present study demonstrated that the milk fat had not
a signiﬁcant effect on the activity of free and encapsulated BLS P34,
but inﬂuenced on the ability of bacteriocin to inhibit
L. monocytogenes in ﬂuid milk. The encapsulation of BLS P34 in
nanovesicles of partially puriﬁed soy phosphatidylcholine was
relatively inexpensive as required by the food industry. In general,
free and encapsulated BLS P34 appeared to be effective to control
L. monocytogenes in milk, especially skim milk, suggesting its
potential use as biopreservative in food products. Therefore, the use
of a bacteriocin in combination with nanotechnology was useful to
control an important pathogen in the dairy industry. This research
addresses the feasibility of the use of antimicrobial peptides and
nanotechnology to improve the quality and safety of food. Further
study, regarding the maintenance of antimicrobial activity and
ability of free and encapsulated BLS P34 to inhibit L. monocytogenes
over time, will be conducted for ﬂuid milk and frescal cheese.Acknowledgments
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